Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 19;12:3579–3587. doi: 10.2147/CMAR.S243660

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Hu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Anlotinib attenuates MEK/ERK pathway in KRAS mutant lung cancer cells. (A) Western blot analysis of ERK, p-ERK, MEK, p-MEK in A549 cells after Anlotinib treatment. (B) Western blot analysis of ERK, p-ERK, MEK, p-MEK in NCI-H460 cells after Anlotinib treatment. (C) MAPK signaling pathway in KRAS mutant cancers. *P<0.05, **P<0.01.